News | Magnetic Resonance Imaging (MRI) | February 11, 2016

Expression MR400 warns clinicians of severe medical changes and provides comprehensive approach in monitoring patients undergoing MRI

Philips, FDA 510k clearance, Expression MR400, MRI patient monitor

February 11, 2016 — Royal Philips announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the Expression MR400, a new technology that monitors patients undergoing magnetic resonance imaging (MRI). The MR400 provides intensive care unit (ICU)-comparable, bedside-quality monitoring in the MR suite for all patients, including those with serious medical conditions or who require anesthesia.

In the MR suite, strong electromagnetic fields make it impossible for clinicians to use traditional patient monitors without causing complications with the monitor or degradation of the images. The lack of adequate monitoring is particularly problematic for patients, including children, who require anesthesia when getting an MRI. Without the ability to reliably track key vital signs, clinicians may not know a patient is in distress until it is too late. 

The MR400 is designed not to create image artifacts or other interference from the electromagnetic fields when used according to the labeling, ensuring that patients receive the level of clinical care and monitoring they need. The device monitors the same vital signs that are tracked in the operating room and in the ICU, including heart rate, oxygen and carbon dioxide levels, body and surface temperatures, and blood pressure, and also includes advanced electrocardiogram (ECG) monitoring. Patients with serious medical conditions, including critical care patients or patients undergoing cardiac procedures, can also be monitored with the MR400, regardless of whether they are under anesthesia.

Similar to traditional patient monitors, the MR400 uses intelligent alarms to warn clinicians of severe patient changes, including desaturation, apnea and extreme bradycardia/tachycardia. Clinicians and staff are able to customize the monitor settings for each patient to prioritize warning signals to reduce alarm fatigue. The new monitoring system uses a touch screen with the same interface as other Philips monitors, making it easier for clinicians to view and respond to patient data. 

The MR400 uses wireless technology, connects with the electronic healthcare record and shares information with IntelliBridge Enterprise to seamlessly send and receive patient information across the hospital. This ensures that all care team members have access to the same high-quality patient information.

For more information: www.philips.com


Related Content

News | Prostate Cancer

June 26, 2025 – Quibim, a global provider of quantitative medical imaging solutions, has launched AI-QUAL, a new feature ...

Time June 26, 2025
arrow
News | Image Guided Radiation Therapy (IGRT)

June 25, 2025 — Royal Philips and Indiana-based Methodist Hospitals recently announced the healthcare provider’s ...

Time June 25, 2025
arrow
News | PET-CT

June 23, 2025 — GE HealthCare’s commitment to advancing precision care in cardiology through its molecular imaging ...

Time June 23, 2025
arrow
News | Cardiac Imaging

May 20, 2025 — Royal Philips has launched the RADIQAL (Radiation Dose and Image Quality Trial) trial. This multicenter ...

Time May 27, 2025
arrow
News | Pediatric Imaging

May 13, 2025-- GE HealthCare recently announced the U.S. Food and Drug Administration (FDA) has approved a pediatric ...

Time May 20, 2025
arrow
News | Artificial Intelligence

April 16, 2025 — An artificial intelligence (AI) program trained to review images from a common medical test can detect ...

Time April 16, 2025
arrow
News | Pediatric Imaging

April 10, 2025 — Cincinnati Children’s and GE HealthCare will form a strategic research program focused on driving ...

Time April 10, 2025
arrow
News | Radiology Imaging

Jan. 15, 2025 — University of California, San Francisco (UCSF) Department of Radiology & Biomedical Imaging and GE ...

Time January 27, 2025
arrow
News | Contrast Media

Jan. 10, 2025 – Bayer has announced positive topline results of the Phase III QUANTI studies evaluating the efficacy and ...

Time January 14, 2025
arrow
News | Women's Health

Aug. 19, 2024 — GE HealthCare recently announced a collaboration with the University of California San Diego School of ...

Time August 29, 2024
arrow
Subscribe Now